

Statement in Compliance with Section 172 (1) of the Companies Act 2006

On 1 April 2019, there was a restructuring of the Eakin Healthcare Group. As a result, Eakin Healthcare Limited, a wholly owned subsidiary, transferred its shareholding in Eakin Healthcare Group Limited to Eakin Investments Limited via a distribution in specie. On the same date, Eakin Healthcare Group Limited acquired the entire share capital of Eakin Healthcare Limited from Eakin Investments Limited. Subsequently on the same date, Eakin Healthcare Limited also transferred its entire shareholding in TG Eakin Limited, Pelican Healthcare Limited, Pelican Feminine Healthcare Limited, Respond Healthcare Limited and Eakin R&D Limited to Eakin Healthcare Group Limited via a dividend in specie. The stakeholders impacted by the decision were the shareholders of the companies and the Group. However, as it was an internal restructure of the Group, there was no impact on the operation of the companies within the Group. The restructure was conducted to formalise the position of Eakin Healthcare Group Limited as a management services company to the various trading companies within the Group. The long-term impact of the decision is that Eakin Healthcare Group Limited is in a better position to provide these management services and oversight to its subsidiaries. Eakin Healthcare Group Limited will prepare consolidated year end accounts which show the consolidated position of the trading companies.

On 1 April 2019, a group subsidiary company, Eakin BV, incorporated in the Netherlands, commenced trading in the direct marketing and sale of ostomy products following an agreement whereby Eakin BV acquired the goodwill of the former third party independent distributor in the Netherlands. The stakeholders impacted by this decision included the employees and the customers of Eakin BV. Key customers were visited by management personnel from the Eakin Healthcare Group to communicate the change and how this would impact them, if at all. The employees of the former distributor were notified of the decision by their employer and by Eakin Healthcare Group and all employees of the original third party distributor became employees of Eakin BV. The only supplier of the original distributor was TG Eakin Limited, and this continues to be the case for Eakin BV. As a result, there was no significant impact or change to the stakeholders. Arising from communications with key stakeholders, some suppliers negotiated new terms with Eakin BV, while employees communicated their preferences for benefits. These views were taken into consideration and were accommodated where possible. The expected long-term impact on the Group is that we anticipate increased sales and profitability. We now have closer engagement with the Netherlands market, and a trading subsidiary in the EU following Brexit.

On 30 August 2019, there was a further restructure of the Eakin Healthcare Group. Eakin Healthcare Group Limited transferred its shareholding in Eakin BV to TG Eakin Limited via a share for share exchange. This decision was made as it would create an international group of companies within the Eakin Healthcare Group, creating clearer alignment of the international businesses and a stronger reporting structure. As the transfer of ownership was intra-group, the operations of Eakin BV were not impacted and had no impact on the identified stakeholders; the employees of Eakin BV.

On 30 September 2019, following a strategic review of Pelican Feminine Healthcare Limited's activities, and that of its wholly owned subsidiary, Pelispec Limited, the decision was made to dispose of the business of the design, manufacture and sale of speculums and related accessories through the sale of the entire shareholding in Pelispec Limited to a third party. Directors identified that this decision had an impact on certain employees, customers and suppliers. Communication with employees was through face to face consultations, as well as written communication to provide any updates on the sale of the company. The employees were transferred from Pelican Feminine Healthcare Limited to Pelispec Limited. In addition, the purchaser of Pelispec Limited consulted with the employees about moving the operations to a new location of the company. Due to the


Statement in Compliance with Section 172 (1) of the Companies Act 2006

confidentiality of the sale, the customers and suppliers were notified at the exchange of contracts. All customers were written to, and key customers were visited. During these visits, any concerns were addressed. A new subcontracted third party was engaged to manufacture the Pelispec products for the new owners, which impacted on the suppliers. However, as this new manufacturer used the majority of the same suppliers, we believe the impact was minimised.

On 24 February 2020, Eakin Investments Limited changed its name to Dunrogan Limited.

Signed on behalf of the Board of Directors:

TG Eakin

A handwritten signature in black ink, appearing to read 'TG Eakin', written over the printed name.